We report a 31-year-old Chinese man with bronchial carcinoid tumour and bilateral phaeochromocytoma. His sister also gave a history of bilateral carotid body paraganglioma. This case demonstrates the importance of screening for other endocrine disorders in patients with foregut carcinoid tumours.
Introduction
Griffiths' first identified the association between duodenal carcinoid, phaeochromocytoma, and neurofibromatosis and proposed that this represented a specific multiple endocrine neoplasia syndrome which he classified as MEN type III a. We now report a patient in whom a bronchial carcinoid tumour coexisted with phaeochromocytoma. There was also a history of bilateral carotid body tumours in a sibling.
Case history
A 31-year-old Chinese man first developed episodic attacks of tremor, flushing, diarrhoea, and sweating in early 1988. These attacks came on several times a month and lasted 5 Clinical examination revealed a right thoracotomy scar. There was no palpable goitre nor skin nodule. Pulse was 80 beats/min. Blood pressure was 140/90 mmHg. There was no postural hypotension. The rest of the examination was unremarkable. The results of biochemical investigations are given in the box.
Thyroid ultrasound showed a 7-mm nodule at the lower pole of the right thyroid. Fine needle aspiration cytology was normal. Metaiodo-benzylguanidine scan suggested a region of rather diffuse uptake which was only slightly increased above background in the right upper quadrant of the abdomen and appeared as low-grade liver uptake. MRI of his neck and upper thorax was normal. Venous catheterisation and sampling suggested a noradrenalinesecreting phaeochromocytoma of the right adrenal. The left renal vein could not be catheterized. He was treated with phenoxybenzamine and propanolol in preparation for adrenalectomy.
At operation a 5 x 2 x 4 cm tumour was found on the right adrenal and a 4.5 x (normal 63-146) * normal renal, liver and thyroid function * normal serum calcium and phosphate levels * normal dexamethasone suppression test phaeochromocytoma, and a family history of paraganglioma. Interestingly, neither he nor any member of his family has evidence of neurofibromatosis. The coexistence of these neuroendocrine tumours is unlikely to be coincidental.
Lubarsch2 first described a carcinoid tumour in 1888. In 1962, Williams3 classified carcinoid according to embryologic origin into derivatives of foregut (thymus, bronchus, stomach, and duodenum), midgut and hindgut (jejunum, ileum, appendix, colon, and rectum). Most reported carcinoid series4-6 indicate foregut carcinoids to be less common than midgut-and hindgut-derived carcinoids, accounting for less than 20% of all carcinoids. On the other hand, in patients with carcinoid tumours and other endocrine tumours, the carcinoid tumours are usually of foregut origin.4'5 Foregut carcinoids can produce a variety of hormones such as ACTH and somatostatin. In addition to the difference in anatomical distribution, there is also a difference in sexual predominance. Carcinoids not associated with other endocrine tumours are evenly distributed between men and women. In patients with other associated endocrine tumours, bronchial carcinoids are more common in women (79%) and tend to be benign while more men (88%) have thymic carcinoids which are usually malignant.6
Underdahl7 was the first to note the presence of a bronchial carcinoid in a patient with The predominance of foregut carcinoid may be embryologically associated with the development of multiple endocrine neoplasia. Histological evidence suggests that bronchial carcinoid, phaeochromocytoma, and paraganglioma are tumours of the peripheral nervous tissues. Although bronchial carcinoid derives from Kultchitskey cells of bronchial epithelium,'4"'5 histologically, it can be almost identical to phaeochromocytoma and paraganglioma which arises from the chromaffin cells. '6 The causes of these neuroendocrine tumours have not been well established. Stephen"3 proposed the possibility of production of a local nerve-derived trophic factor in the pathogenesis of these tumours, whereas Griffiths"2 suggested a genetic defect leading either to a production of a circulating growth-stimulating substance or to an abnormality of the intracellular growth-control mechanisms rendering the cells more likely to develop neoplasia. There is, however, no evidence of racial differences in the incidence of these tumours.
